ASX Announcement – 1 August 2023

EXPIRY OF ATM FACILITY

Resonance Health Ltd (ASX: RHT) (**Resonance** or **Company**) advises that the Controlled Placement Agreement executed by the Company and Acuity Capital on 18 April 2019 and then extended on 30 June 2021 (**CPA**), has expired as of 31 July 2023.

The CPA established an at-the-market standby equity capital facility (**ATM Facility**) providing Resonance with standby equity capital. As security for the ATM Facility, the Company issued Acuity Capital with 20,000,000 collateral shares.

Given the ATM Facility has now expired, the parties have agreed to the return and cancellation of the 20 million collateral shares for nil consideration in accordance with the terms of the CPA (**Buyback**). The Buyback will be implemented in accordance with Part 2J.1 of the *Corporations Act 2001* (Cth) and will be subject to shareholder approval.

The Company intends to seek the requisite shareholder approval for the Buyback at its upcoming 2023 Annual General Meeting (**AGM**). Further information on the resolution will be provided in the AGM Notice of Meeting & Explanatory Memorandum.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

Andrew Harrison – Chief Executive Officer
E: andrewh@resonancehealth.com
P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®,** a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®,** an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.

- **HepaFatScan®,** an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart ®,** an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®,** an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2*,** the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US

/Resonance-Health-Ltd /ResonanceHealth /ResonanceHealthLtd